Authors: Martha Powell, Future Science Group
The US FDA has accepted a Biologics License Application for Sanofi Pasteur’s (Lyon, France) dengue vaccine, Dengvaxia®, despite its controversial past.
The dengue vaccine candidate has been granted priority review by the regulatory body, as it would represent the first and only medical prevention tool against dengue – a considerable unmet need. This means a decision must be filed within 6 months.
Restricted Content / Members Only
